drugset / Trial / NCT03111121

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

NCT03111121

Phase 4 Completed 79 enrolled West Virginia University
RandomizedParallel-groupSingle-blindTreatment

Summary

Use of Muscle relaxant and reversal with Sugammadex at end of airway procedures will reduce the time to extubation after end of procedure

Timeline

Start
2017-05-04
Primary completion
2018-06-22
Completion
2019-05-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glycopyrrolate Small molecule 0.01 mg/kg
Comparator Neostigmine Other / unclassified 0.04 mg/kg
Comparator Sugammadex Other / unclassified 4 mg/kg

Indications

No indication recorded.